Northland Securities Predicts Increased Earnings for Nephros

Nephros Inc. (NASDAQ:NEPH – Free Report) – Stock analysts at Northland Securities boosted their FY2026 earnings estimates for shares of Nephros in a report released on Friday, November 6th. Northland Securities analyst B. Brooks now forecasts that the company will post earnings of $0.18 per share for the year, up from their previous forecast of $0.15. Northland Securities currently has a “Market Perform” rating and a $4.00 target price on the stock. The consensus estimate for Nephros’ current full-year earnings is $0.18 per share. Northland Securities also issued estimates for Nephros’ Q3 2027 earnings at $0.07 EPS and FY2027 earnings at $0.32 EPS.

Nephros (NASDAQ:NEPH – Get Free Report) last issued its earnings results on Thursday, November 5th. The company reported $0.05 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.02 by $0.03. Nephros had a net margin of 8.86% and a return on equity of 11.97%. The business had revenue of $5.62 million during the quarter, compared to the consensus estimate of $5.49 million.

Several other research analysts have also recently weighed in on NEPH. Benchmark reissued a “speculative buy” rating on shares of Nephros in a report on Tuesday, August 18th. Zacks Research upgraded Nephros to a “hold” rating in a report on Monday, July 20th. Finally, Weiss Ratings reaffirmed a “hold (c)” rating on shares of Nephros in a research report on Friday, October 30th. One equities research analyst has rated the stock with a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat.com, Nephros presently has an average rating of “Hold” and an average price target of $4.00.

Read Our Latest Analysis on NEPH

Nephros Stock Performance

NEPH stock opened at $2.79 on Monday. The firm has a market capitalization of $30.33 million, a PE ratio of 15.50 and a beta of 1.76. Nephros has a 1-year low of $2.66 and a 1-year high of $6.42. The business’s 50 day simple moving average is $3.79 and its 200 day simple moving average is $3.65.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in NEPH. Cornerstone Capital Inc. acquired a new position in Nephros during the second quarter valued at approximately $459,000. Bard Associates Inc. acquired a new stake in shares of Nephros in the 2nd quarter valued at $421,000. Navellier & Associates Inc. boosted its holdings in shares of Nephros by 179.6% in the 2nd quarter. Navellier & Associates Inc. now owns 53,479 shares of the company’s stock valued at $191,000 after purchasing an additional 34,353 shares in the last quarter. Dimensional Fund Advisors LP increased its stake in shares of Nephros by 52.5% in the 1st quarter. Dimensional Fund Advisors LP now owns 20,745 shares of the company’s stock valued at $62,000 after purchasing an additional 7,144 shares during the last quarter. Finally, BlackRock Inc. bought a new position in shares of Nephros in the 2nd quarter valued at $67,000. 41.10% of the stock is currently owned by institutional investors and hedge funds.

Nephros Company Profile

(Get Free Report)

Nephros, Inc is a medical device company that develops and sells filtration products designed to improve water quality and reduce the risk of waterborne contamination. Its technologies are based primarily on ultrafiltration membranes that remove bacteria, viruses, endotoxins, cysts and other impurities from water.

The company serves the healthcare market with filtration systems for hemodialysis and infection-control applications. Its products are designed for use in hospitals, dialysis centers and other healthcare facilities where purified water is important for patient care and clinical operations.

Nephros also offers commercial water-filtration products for applications such as foodservice, hospitality, commercial buildings and healthcare facilities.

Featured Articles

Earnings History and Estimates for Nephros (NASDAQ:NEPH)

Receive News & Ratings for Nephros Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nephros and related companies with MarketBeat.com's FREE daily email newsletter.